To validate that increasing soluble ACE2 alone could also modulate diabetes-associated atherosclerosis, we treated diabetic ApoE KO mice with rmACE2 (1 mg/kg/alternate day IP) for 6 weeks. The gene discussed is APOE; the disease is atherosclerosis.